A necessary feature for sustained and progressive melanoma growth, MYC expression can be suppressed by treatment with BRAF/MEK inhibitors leading to tumor shrinkage, manifesting as clinical and/or pathological response; recovery of the overexpression of MYC has been shown to drive resistance to these treatments [18]. Here, BRAF is linked to melanoma.